106 unknown. 106 Phase 2, 23 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 106 | Unknown 106 |
| Phase 1 | 23 | Unknown 23 |
| Phase 3 | 4 | Unknown 4 |
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL Polatuzumab vedotin, Rituximab, Orelabrutinib - Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | Affiliated Hospital of Nantong University | 30 | 2024-08-01 | 2025-02-04 |
| Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL ZR2-ICE - Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory | Phase 2 | Unknown | RenJi Hospital | 20 | 2023-10-12 | 2024-03-13 |
| CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma CD19-targeted Chimeric Antigen Receptor(CAR) T Cells - Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | Shanghai Ming Ju Biotechnology Co., Ltd. | 10 | 2023-08-17 | 2024-08-21 |
| Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors Zanubrutinib, Rituximab, Cyclophosphamide - Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | Liaoning Cancer Hospital & Institute | 30 | 2023-08-01 | 2023-07-27 |
| Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma Zanubrutinib, Polatuzumab vedotin and Rituximab - Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | Peng Liu | 35 | 2023-07-20 | 2023-07-11 |
| Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Mitoxantrone Hydrochloride Liposome Injection - Diffuse Large B-Cell Lymphoma | Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 104 | 2023-07-10 | 2024-02-08 |
| A Combination Study of CAR-T Therapy in r/r B-NHL BTK inhibitor, PD-1 inhibitor - Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 48 | 2023-06-10 | 2023-08-01 |
| Decitabine and Anti-PD-1 in R/R DLBCL Low-Dose Decitabine plus anti-PD-1 - Diffuse Large B Cell Lymphoma, Relapse/Recurrence | Phase 2 | Unknown | Chinese PLA General Hospital | 20 | 2023-05-15 | 2023-05-09 |
| Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers BR1733 - Advanced Cancer, Follicular Lymphoma | Phase 1 / Phase 2 | Unknown | Shanghai Blueray Biopharma Co., Ltd. | 191 | 2023-04-19 | 2024-08-07 |
| Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI Orelabrutinib combined with R-CDOP regimen - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 62 | 2023-03-30 | 2024-03-04 |
| Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission Zanubrutinib - Diffuse Large B-cell Lymphoma (DLBCL) | Phase 2 | Unknown | LanZhou University | 15 | 2022-10-30 | 2022-10-27 |
| Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Jianfeng Zhou | 55 | 2022-10-10 | 2022-10-12 |
| Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients Chidamide, Azacitidine, obinutuzumab - Diffuse Large B-Cell Lymphoma | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 23 | 2022-09-30 | 2023-04-21 |
| Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL Orelabrutinib, Rituximab, CHOP-like Regimen - Diffuse Large B-Cell Lymphoma | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 46 | 2022-07-27 | 2023-02-03 |
| The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma. Zanubrutinib+Rituximab+Lenalidomide, RCHOP/RCDOP - Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | First Affiliated Hospital of Wenzhou Medical University | 150 | 2022-06-15 | 2022-06-23 |
| Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin - Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 54 | 2022-05-15 | 2022-03-07 |
| A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma Zanubrutinib, Lenalidomide, Rituximab - Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 36 | 2022-02-01 | 2022-03-11 |
| A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression Zanubrutinib + R-CHOP - Diffuse Large B-cell Lymphoma(DLBCL) | Phase 2 | Unknown | Fudan University | 41 | 2022-01-18 | 2024-05-17 |
| ZR-CHOP in DLBCL With Specific Gene Abnormality zanubrutinib - Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | Fudan University | 62 | 2022-01-04 | 2022-03-22 |
| ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL Rituximab, Lenalidomide, Zanubrutinib and RCHOP - Diffuse Large B Cell Lymphoma | Phase 2 | Unknown | Zhejiang Cancer Hospital | 31 | 2021-10-01 | 2023-10-17 |
Showing 20 of 106. Sign in to see all of them.
Lymphoma, Follicular (26) · Lymphoma, Non-Hodgkin (23) · Lymphoma, Mantle-Cell (22) · Leukemia, Lymphocytic, Chronic, B-Cell (21) · Lymphoma (21) · Burkitt Lymphoma (16) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (15) · Recurrence (14) · Lymphoma, Large-Cell, Immunoblastic (13) · Lymphoma, B-Cell, Marginal Zone (11) · Leukemia (8) · Hodgkin Disease (7) · Lymphoma, B-Cell (7) · Multiple Myeloma (7)
Hemic and Lymphatic Diseases (106) · Lymphatic Diseases (105) · Lymphoproliferative Disorders (105) · Immune System Diseases (104) · Immunoproliferative Disorders (104) · Neoplasms by Histologic Type (104) · Neoplasms (102) · Lymphoma, B-Cell (99) · Lymphoma (85) · Lymphoma, Non-Hodgkin (83) · Disease Attributes (31) · Pathologic Processes (31) · Pathological Conditions, Signs and Symptoms (31) · Hematologic Diseases (25) · Leukemia, Lymphoid (25)
Rituximab (40) · Cyclophosphamide (24) · Vincristine (14) · Doxorubicin (13) · Prednisone (12) · Lenalidomide (11) · Cytarabine (10) · Etoposide (9) · Gemcitabine (7) · zanubrutinib (7) · Cisplatin (6) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (6) · Dexamethasone (5) · Antigens, CD19 (4) · Bendamustine Hydrochloride (4)
Ruijin Hospital (7) · Fudan University (5) · Asan Medical Center (4) · The First Affiliated Hospital with Nanjing Medical University (4) · Chinese PLA General Hospital (3) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (3) · Auxilio Mutuo Cancer Center (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Chinese Academy of Medical Sciences (2) · Fondazione Italiana Linfomi - ETS (2) · Herbert Irving Comprehensive Cancer Center (2) · Huiqiang Huang (2) · Nanfang Hospital, Southern Medical University (2) · Shanghai Ming Ju Biotechnology Co., Ltd. (2) · Southwest Hospital, China (2)
China (57) · United States (17) · South Korea (6) · Italy (5) · Canada (3) · Puerto Rico (3) · United Kingdom (3) · Sweden (2) · Switzerland (2) · Australia (1) · Austria (1) · Denmark (1) · Finland (1) · France (1) · Germany (1)
David G. Savage, MD (2) · Fernando Cabanillas, MD (2) · Jieping Chen, MD,PhD (2) · Michele Spina, MD (2) · Ye Guo, MD (2) · A. McMillan (1) · Baorui Liu, MD (1) · Barbara Pro, MD (1) · Bei Liu, MD (1) · Bo Zhu, M.D., Ph.D. (1) · Carol Brannan, BS, BSN (1) · Cheng Qian, PhD (1) · Cheolwon Suh, MD, PhD (1) · Christos E. Emmanouilides, MD (1) · David Cunningham, MD FRCP (1)
PMID 34515338, PMID 15107815, PMID 18213528, PMID 18824292, PMID 1950172, PMID 20686505, PMID 21390126, PMID 21796119, PMID 22080169, PMID 22339555, PMID 22362161, PMID 23228045, PMID 23753028, PMID 23799873, PMID 24721323, PMID 25444722, PMID 25652253, PMID 25712263, PMID 28054442, PMID 28356247, PMID 29263894, PMID 29748444, PMID 29752199, PMID 30620669, PMID 31039052, PMID 32187361, PMID 32245502, PMID 32464282, PMID 32989495, PMID 33097085, PMID 33382529, PMID 34568066, PMID 35418080, PMID 36053875, PMID 36102758, PMID 36842849, PMID 38237077, PMID 38579729, PMID 39319495, PMID 39572395, PMID 39923042, PMID 40532125, PMID 40656663, PMID 40888120, PMID 41136989, PMID 41656201, PMID 42386710
2005 (1), 2009 (1), 2015 (1), 2016 (1), P30CA015083 (1), P30CA060553 (1)